



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Hengwen Chen,  
✉ [chenhengwen@163.com](mailto:chenhengwen@163.com)  
Xuanhui He,  
✉ [hexuanzi1646@sina.com](mailto:hexuanzi1646@sina.com)

<sup>†</sup>These authors have contributed equally to this work and share first authorship

RECEIVED 08 April 2025  
ACCEPTED 10 April 2025  
PUBLISHED 24 April 2025

## CITATION

Yao B, Ma J, Ran Q, Chen H and He X (2025)  
Corrigendum: Mechanism of *Valeriana officinalis* L. extract improving atherosclerosis by regulating PGC-1 $\alpha$ /Sirt3/Epac1 pathway.  
*Front. Pharmacol.* 16:1607975.  
doi: 10.3389/fphar.2025.1607975

## COPYRIGHT

© 2025 Yao, Ma, Ran, Chen and He. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Mechanism of *Valeriana officinalis* L. extract improving atherosclerosis by regulating PGC-1 $\alpha$ /Sirt3/Epac1 pathway

Bo Yao<sup>1,2†</sup>, Jingzhuo Ma<sup>1†</sup>, Qingzhi Ran<sup>1</sup>, Hengwen Chen<sup>1\*</sup> and Xuanhui He<sup>1\*</sup>

<sup>1</sup>Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, <sup>2</sup>School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, China

## KEYWORDS

*Valeriana officinalis* L., extract, atherosclerosis, PGC-1 $\alpha$ /Sirt3/Epac1 pathway, mitochondrial damage, traditional Chinese medicine

## A Corrigendum on

[Mechanism of \*Valeriana officinalis\* L. extract improving atherosclerosis by regulating PGC-1 \$\alpha\$ /Sirt3/Epac1 pathway](#)

by Yao B, Ma J, Ran Q, Chen H and He X (2024). *Front. Pharmacol.* 15:1483518. doi: [10.3389/fphar.2024.1483518](https://doi.org/10.3389/fphar.2024.1483518)

In the published article, there was an error in the **Funding** statement. Two important pieces of funding support [“the National Natural Science Foundation of China (No. 82205091)” and “Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (CI2021A04619)”] were erroneously omitted. The correct **Funding** statement appears below.

## Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the National Natural Science Foundation of China (No. 82205091 and No. 82074396), the Clinical Research Funds for the Centralized High level Chinese Medicine Hospitals (HLCMHPP2023077), Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (CI2023CO22YL and CI2021A04619).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.